INSIGHTS ON DRUG DEVELOPMENT

• How CRISPR And LNP Accelerate Therapeutic Innovation Through Analytics

  CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.

• Remote Measurements For Bulk Samples

  Remote Raman spectroscopy enables accurate material identification at long distances without complex focusing. Learn how pathlength, sample properties, and substrate choice impact signal quality.

• A Human-Relevant Model Of The Liver Sinusoid

  This organ-on-a-chip model minimizes drug absorption while maintaining the essential architecture. Explore the specifications of this product engineered to model the human liver.

• Formulation Strategies For Enabling "Undevelopable" Compounds

  KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.

• Accelerating Drug Development: Solid State Chemistry And Strategic Outsourcing

  5/6/2026

  Discover how phase‑appropriate solid‑state chemistry and strategic outsourcing reduce risk, speed development timelines, and enable confident solid‑form selection for complex small‑molecule programs.

• Amorphous Stability: Mesoporous Silica For Poor Glass Formers

  6/5/2025

  Discover how mesoporous silica outperforms polymeric solid dispersions in stabilizing poor glass formers, as well as how it offers a novel approach to enhance amorphous drug stability and bioavailability.

• Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds

  5/6/2026

  Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

• A New Framework For Identifying Nitrosamine Risks And Derisking Products

  6/18/2024

  Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to prioritize risk mitigation strategies and ensure compliance.

• Doubling Up For Speed In Biomanufacturing

  12/12/2025

  Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.